ArticleMMWR. Morbidity and mortality weekly report2020
Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018.
Article in MMWR. Morbidity and mortality weekly report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.Arthritis care & research · 2022Guideline
- 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.Arthritis & rheumatology (Hoboken, N.J.) · 2022Guideline
- The prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual and transgender populations: a systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Opioid treatment program-integrated facilitated telemedicine for hepatitis C treatment: a hybrid effectiveness-implementation analysis.BMC complementary medicine and therapies · 2025Trial
- Peer-Assisted Telemedicine for Hepatitis C in People Who Use Drugs: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.Journal of viral hepatitis · 2021Trial
- Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection.The New England journal of medicine · 2021Trial
- Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016-2020.American journal of preventive medicine · 2026Article
- IMPAACT 2041: Designing the Study of Glecaprevir/Pibrentasvir Treatment During Pregnancy.Open forum infectious diseases · 2026Article
- Recent trends in Early-Onset cancer incidence rates.Journal of the National Cancer Institute · 2026Article
- Projected health benefits and cost offsets from the United States National Hepatitis C Elimination Initiative.Nature communications · 2026Article
- Identifying communities at elevated risk of hepatitis C infection in Los Angeles County: an ecological study using machine learning.BMC public health · 2026Article
- Improvements in substance use and social determinants of health associated with hepatitis C treatment initiation and sustained virologic response in opioid treatment programs.Addictive behaviors reports · 2026Article
- Recent Advances in the Epidemiology, Screening, and Management of Hepatitis C Virus Infection in Pregnancy.Gastroenterology & hepatology · 2026Article
- Non-fatal Overdose and Associated Factors Among People Who Use Opioids: Findings From a Cross-sectional Study.Journal of community health · 2025Article
- Hepatitis C Surveillance in the United States: Past, Present, and Future.Public health reports (Washington, D.C. : 1974) · 2025Review
- Trends in Hepatitis C and Hepatitis B Deaths Identify Successes and Disparities, Alameda County, CA, 2005 - 2022.Gastroenterology research · 2025Article
- Drug treatment and support service utilization amidst the COVID-19 pandemic among people who inject drugs in Baltimore, Maryland: An interrupted time-series analysis, 2015-2022.The International journal on drug policy · 2025Article
- Newly Reported Chronic Hepatitis C Among Adults - Alaska, 2016-2023.MMWR. Morbidity and mortality weekly report · 2025Article
- Predictors of Acute HCV Incidence in People with HIV: Insights from a Long-term Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatitis C is a leading cause of death from liver disease in the United States. Acute hepatitis C infection is often asymptomatic, and >50% of cases will progress to chronic infection, which can be life-threatening. Hepatitis C can be diagnosed with a blood test and is curable, yet new cases of this preventable disease are increasing.
methodsNational Notifiable Diseases Surveillance System data were analyzed to determine the rate of acute hepatitis C cases reported to CDC by age group and year during 2009-2018 and the number and rate of newly reported chronic cases in 2018 by sex and age. The proportion of adults aged ≥20 years with hepatitis C who reported having ever been told that they had hepatitis C was estimated with 2015-2018 National Health and Nutrition Examination Survey data.
resultsDuring 2018, a total of 3,621 cases of acute hepatitis C were reported, representing an estimated 50,300 cases (95% confidence interval [CI] = 39,800-171,600). The annual rate of reported acute hepatitis C cases per 100,000 population increased threefold, from 0.3 in 2009 to 1.2 in 2018, and was highest among persons aged 20-29 (3.1) and 30-39 years (2.6) in 2018. A bimodal distribution of newly reported chronic hepatitis C cases in 2018 was observed, with the highest proportions among persons aged 20-39 years and 50-69 years. Only 60.6% (95% CI = 46.1%-73.9%) of adults with hepatitis C reported having been told that they were infected. CONCLUSIONS AND IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Increasing rates of acute hepatitis C among young adults, including reproductive-aged persons, have put multiple generations at risk for chronic hepatitis C. The number of newly reported chronic infections was approximately equal among younger and older adults in 2018. The new CDC hepatitis C testing recommendations advise screening all adults and pregnant women, not just persons born during 1945-1965, and those with risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.